NEW YORK, Jan. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Bill Ackman Eyes New Fund to Bet Against Market Complacency
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 



